10x Genomics, Inc.

NasdaqGS:TXG Stock Report

Market Cap: US$1.8b

10x Genomics Management

Management criteria checks 3/4

10x Genomics' CEO is Serge Saxonov, appointed in Jul 2012, has a tenure of 12.42 years. total yearly compensation is $8.29M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 3.33% of the company’s shares, worth $59.10M. The average tenure of the management team and the board of directors is 2.9 years and 5.5 years respectively.

Key information

Serge Saxonov

Chief executive officer

US$8.3m

Total compensation

CEO salary percentage6.6%
CEO tenure12.4yrs
CEO ownership3.3%
Management average tenure2.9yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

10x Genomics: Deciphering The Preliminary Q3 Earnings

Oct 12

The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

CEO Compensation Analysis

How has Serge Saxonov's remuneration changed compared to 10x Genomics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$183m

Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

Compensation vs Market: Serge's total compensation ($USD8.29M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.

CEO

Serge Saxonov (47 yo)

12.4yrs

Tenure

US$8,286,050

Compensation

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

Leadership Team

NamePositionTenureCompensationOwnership
Serge Saxonov
Co-Founder12.4yrsUS$8.29m3.33%
$ 59.1m
Benjamin Hindson
Co-Founder12.4yrsUS$4.43m2.67%
$ 47.5m
Eric Whitaker
Chief Legal Officer7.4yrsUS$3.88m0.12%
$ 2.1m
Adam Taich
CFO, Treasurerless than a yearno datano data
Jim Goodrich
Chief of Global Operationsless than a yearno datano data
Michael Schnall-Levin
Founding Scientist & CTO2.9yrsno datano data
Alexander Wong
Chief Information Officerless than a yearno datano data
Cassie Corneau
Manager of Investor Relations & Strategic Financeno datano datano data
Rebecca Port
Chief People Officer3.9yrsno datano data
Mennah Moustafa
Chief Commercial Officerless than a yearno datano data
Jens Durruthy
Associate Director of Product Managementno datano datano data

2.9yrs

Average Tenure

48.5yo

Average Age

Experienced Management: TXG's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Serge Saxonov
Co-Founder12.4yrsUS$8.29m3.33%
$ 59.1m
Benjamin Hindson
Co-Founder12.4yrsUS$4.43m2.67%
$ 47.5m
Kimberly Popovits
Independent Director4.8yrsUS$338.71k0.0038%
$ 67.7k
John Stuelpnagel
Independent Chairman11.3yrsUS$403.59k2.02%
$ 35.8m
Shehnaaz Suliman
Independent Director5.3yrsUS$336.39k0.0038%
$ 67.7k
Alan Mateo
Directorless than a yearno datano data
Sridhar Kosaraju
Independent Director5.7yrsUS$346.39k0.029%
$ 520.0k
Sarah Polonius-Teichmann
Directorless than a yearno datano data

5.5yrs

Average Tenure

52yo

Average Age

Experienced Board: TXG's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:07
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

10x Genomics, Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Luke SergottBarclays
Michael RyskinBofA Global Research